IMRX (immuneering.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Immuneering Corp (IMRX)

Immuneering Corporation (IMRX) is a research-based biotech company with no sales, whose development depends on external investments. The sector is protected by stable demand for healthcare, regardless of economic conditions. The EV/Sales ratio trend reflects market expectations, where 0.00 is the current value of the indicator. However, geopolitical fragmentation and sanctions complicate the conduct of global trials and the procurement of necessary biomaterials.

immuneering.com (IMRX): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Immuneering (IMRX)

- price and consensus price forecast:
- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:Immuneering Corporation IMRX
Product sample of immuneering.com

This indicator compares the total enterprise value, adjusted for net debt, against annual sales volume. For Immuneering Corporation (IMRX), which utilizes outsourced manufacturing and a tumor analysis IT platform, this allows for an assessment of the capitalization efficiency of its intellectual property. By analyzing the enterprise value-to-sales multiple, an investor can identify pricing anomalies. Line stability amidst market volatility may signal manipulative price support.